{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:41Z","timestamp":1793730941702,"version":"4.6.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dyslipidaemia, especially elevated low-density lipoprotein cholesterol (LDL-C), is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Dyslipidaemia remains underdiagnosed and undertreated. Dyslipidemia is highly prevalent in Germany. Even among patients with high- and very-high cardiovascular risk, LDL-C targets are often not achieved. This paper highlights key lipid parameters beyond LDL-C, such as triglycerides and lipoprotein(a), which contribute to residual cardiovascular risk. Practical guidance to address diagnostic challenges and cardiovascular risk assessment, especially in younger adults and those with risk modifiers, is provided. Lifestyle interventions are the basis of therapy. Statins remain the first-line treatment, with additional options including ezetimibe, bempedoic acid, and PCSK9 inhibitors, alone or in combination. Novel lipid-lowering therapies are currently in development and may offer more individualized treatment options in the future. The most important messages from the 2025 Focused Update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias have been incorporated into the paper. While LDL-C targets remain unchanged, important novel recommendations encompass consideration of cardiovascular risk modifiers such as lipoprotein(a) and CRP\/inflammatory diseases. A second important new recommendation is the use of potent early combination therapy after an acute coronary syndrome. Improved awareness, early diagnosis, and evidence-based lipid management are critical for reducing ASCVD burden. This paper is aimed at supporting clinicians in optimizing lipid diagnostics and therapy in daily practice.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00392-025-02833-y","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:45:35Z","timestamp":1767865535000},"page":"185-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A practical guide to the management of dyslipidaemia"],"prefix":"10.1007","volume":"115","author":[{"given":"Patrick M.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius L.","family":"Katzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2833_CR1","doi-asserted-by":"publisher","unstructured":"(2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2100\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(24)00367-2","DOI":"10.1016\/s0140-6736(24)00367-2"},{"issue":"46","key":"2833_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3238\/arztebl.m2022.0314","volume":"119","author":"M Porst","year":"2022","unstructured":"Porst M, Lippe EV, Leddin J, Anton A, Wengler A, Breitkreuz J et al (2022) The burden of disease in Germany at the national and regional level. Dtsch Arztebl Int 119(46):785\u2013792. https:\/\/doi.org\/10.3238\/arztebl.m2022.0314","journal-title":"Dtsch Arztebl Int"},{"issue":"5\u20136","key":"2833_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00103-013-1670-0","volume":"56","author":"C Scheidt-Nave","year":"2013","unstructured":"Scheidt-Nave C, Du Y, Knopf H, Schienkiewitz A, Ziese T, Nowossadeck E et al (2013) Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1). Bundesgesundheitsbl Gesundheitsforschung Gesundheitsschutz 56(5\u20136):661\u2013667. https:\/\/doi.org\/10.1007\/s00103-013-1670-0","journal-title":"Bundesgesundheitsbl Gesundheitsforschung Gesundheitsschutz"},{"issue":"19","key":"2833_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.021024","volume":"10","author":"C Wang","year":"2021","unstructured":"Wang C, Sun Y, Jiang D, Wang C, Liu S (2021) Risk-attributable burden of ischemic heart disease in 137 low- and middle-income countries from 2000 to 2019. J Am Heart Assoc 10(19):e021024. https:\/\/doi.org\/10.1161\/jaha.121.021024","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2833_CR5","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1007\/s12325-022-02266-3","volume":"39","author":"L Beier","year":"2022","unstructured":"Beier L, Wolf M, Willfeld K, Weingaertner O (2022) Patient and physician reported perception on hypercholesterolemia management in primary prevention in Germany: results from a nationwide online survey. Adv Ther 39(9):4315\u20134329. https:\/\/doi.org\/10.1007\/s12325-022-02266-3","journal-title":"Adv Ther"},{"key":"2833_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W M\u00e4rz","year":"2018","unstructured":"M\u00e4rz W, Dippel FW, Theobald K, Gorcyca K, Iorga \u015eR, Ansell D (2018) Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis 268:99\u2013107. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.020","journal-title":"Atherosclerosis"},{"key":"2833_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-025-02751-z","author":"O Weing\u00e4rtner","year":"2025","unstructured":"Weing\u00e4rtner O, Gl\u00fcck S, Werdan K, Schorr J, Thieme D, de la Llave A et al (2025) Lipidsnapshot \u2013 treatment gaps in hypercholesterolemia in patients with atherosclerotic cardiovascular disease documented by office-based cardiologists and general practitioners in Germany. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-025-02751-z","journal-title":"Clin Res Cardiol"},{"key":"2833_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106873","volume":"195","author":"F Galimberti","year":"2023","unstructured":"Galimberti F, Casula M, Olmastroni E (2023) Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. Pharmacol Res 195:106873. https:\/\/doi.org\/10.1016\/j.phrs.2023.106873","journal-title":"Pharmacol Res"},{"key":"2833_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01111-0","author":"J Bor\u00e9n","year":"2025","unstructured":"Bor\u00e9n J, Packard CJ, Binder CJ (2025) Apolipoprotein B-containing lipoproteins in atherogenesis. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-024-01111-0","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"2833_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.025858","volume":"11","author":"T Glavinovic","year":"2022","unstructured":"Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD (2022) Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk. J Am Heart Assoc 11(20):e025858. https:\/\/doi.org\/10.1161\/jaha.122.025858","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2833_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL (2018) Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol 72(10):1141\u20131156","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2833_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1001\/jama.2012.6571","volume":"307","author":"E Di Angelantonio","year":"2012","unstructured":"Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A et al (2012) Lipid-related markers and cardiovascular disease prediction. JAMA 307(23):2499\u20132506. https:\/\/doi.org\/10.1001\/jama.2012.6571","journal-title":"JAMA"},{"issue":"9","key":"2833_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP et al (2015) Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 36(9):539\u2013550. https:\/\/doi.org\/10.1093\/eurheartj\/eht571","journal-title":"Eur Heart J"},{"issue":"22","key":"2833_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P et al (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365(22):2078\u20132087","journal-title":"N Engl J Med"},{"issue":"13","key":"2833_CR15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis the ASTEROID Trial. JAMA 295(13):1556\u20131565. https:\/\/doi.org\/10.1001\/jama.295.13.jpc60002","journal-title":"JAMA"},{"issue":"2","key":"2833_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jacc.2021.05.011","volume":"78","author":"B Ibanez","year":"2021","unstructured":"Ibanez B, Fern\u00e1ndez-Ortiz A, Fern\u00e1ndez-Friera L, Garc\u00eda-Lunar I, Andr\u00e9s V, Fuster V (2021) Progression of early subclinical atherosclerosis (PESA) study. J Am Coll Cardiol 78(2):156\u2013179. https:\/\/doi.org\/10.1016\/j.jacc.2021.05.011","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2833_CR17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/joim.13362","volume":"290","author":"Z Chen","year":"2021","unstructured":"Chen Z, Schunkert H (2021) Genetics of coronary artery disease in the post-GWAS era. J Intern Med 290(5):980\u2013992. https:\/\/doi.org\/10.1111\/joim.13362","journal-title":"J Intern Med"},{"issue":"16","key":"2833_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/eurheartj\/ehac783","volume":"44","author":"PE St\u00fcrzebecher","year":"2023","unstructured":"St\u00fcrzebecher PE, Katzmann JL, Laufs U (2023) What is \u201cremnant cholesterol\u201d? Eur Heart J 44(16):1446\u20131448. https:\/\/doi.org\/10.1093\/eurheartj\/ehac783","journal-title":"Eur Heart J"},{"issue":"5","key":"2833_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/atvbaha.123.320175","volume":"44","author":"BN Wadstr\u00f6m","year":"2024","unstructured":"Wadstr\u00f6m BN, Pedersen KM, Wulff AB, Nordestgaard BG (2024) Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apoB: a cohort study. Arterioscler Thromb Vasc Biol 44(5):1144\u20131155. https:\/\/doi.org\/10.1161\/atvbaha.123.320175","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2833_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","volume":"286","author":"M Balling","year":"2019","unstructured":"Balling M, Langsted A, Afzal S, Varbo A, Davey Smith G, Nordestgaard BG (2019) A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals. Atherosclerosis 286:97\u2013104. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.05.011","journal-title":"Atherosclerosis"},{"issue":"4","key":"2833_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG (2013) Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61(4):427\u2013436. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026","journal-title":"J Am Coll Cardiol"},{"key":"2833_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176338","volume":"966","author":"A Attiq","year":"2024","unstructured":"Attiq A, Afzal S, Ahmad W, Kandeel M (2024) Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol 966:176338. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176338","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2833_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ et al (2019) Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 321(4):364\u2013373. https:\/\/doi.org\/10.1001\/jama.2018.20045","journal-title":"JAMA"},{"issue":"3","key":"2833_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","volume":"48","author":"J Scherer","year":"2014","unstructured":"Scherer J, Singh VP, Pitchumoni CS, Yadav D (2014) Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol 48(3):195\u2013203. https:\/\/doi.org\/10.1097\/01.mcg.0000436438.60145.5a","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"2833_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00392-017-1106-1","volume":"106","author":"W M\u00e4rz","year":"2017","unstructured":"M\u00e4rz W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A et al (2017) HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol 106(9):663\u2013675. https:\/\/doi.org\/10.1007\/s00392-017-1106-1","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"2833_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1055\/a-1516-2731","volume":"148","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein A, M\u00e4rz W, Laufs U (2023) HDL - Quo vadis. Dtsch Med Wochenschr 148(10):627\u2013635. https:\/\/doi.org\/10.1055\/a-1516-2731","journal-title":"Dtsch Med Wochenschr"},{"issue":"4","key":"2833_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/cvr\/cvab136","volume":"118","author":"L Zeng","year":"2022","unstructured":"Zeng L, Moser S, Mirza-Schreiber N, Lamina C, Coassin S, Nelson CP et al (2022) Cis-epistasis at the LPA locus and risk of cardiovascular diseases. Cardiovasc Res 118(4):1088\u20131102. https:\/\/doi.org\/10.1093\/cvr\/cvab136","journal-title":"Cardiovasc Res"},{"issue":"39","key":"2833_CR28","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925\u20133946. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"},{"issue":"1","key":"2833_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"1","key":"2833_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2013.12.016","volume":"233","author":"MR Langlois","year":"2014","unstructured":"Langlois MR, Descamps OS, van der Laarse A, Weykamp C, Baum H, Pulkki K et al (2014) Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM collaborative project group. Atherosclerosis 233(1):83\u201390. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.016","journal-title":"Atherosclerosis"},{"issue":"7","key":"2833_CR31","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/circulationaha.114.010001","volume":"130","author":"B Doran","year":"2014","unstructured":"Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ et al (2014) Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 130(7):546\u2013553. https:\/\/doi.org\/10.1161\/circulationaha.114.010001","journal-title":"Circulation"},{"key":"2833_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100053","volume":"62","author":"C Yeang","year":"2021","unstructured":"Yeang C, Witztum JL, Tsimikas S (2021) Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 62:100053. https:\/\/doi.org\/10.1016\/j.jlr.2021.100053","journal-title":"J Lipid Res"},{"issue":"11","key":"2833_CR33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum Joseph L et al (2022) Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol 79(11):1035\u20131046. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.032","journal-title":"J Am Coll Cardiol"},{"issue":"9438","key":"2833_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937\u2013952. https:\/\/doi.org\/10.1016\/s0140-6736(04)17018-9","journal-title":"Lancet"},{"issue":"1","key":"2833_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0735-1097(90)90203-2","volume":"15","author":"WB Kannel","year":"1990","unstructured":"Kannel WB (1990) Bishop lecture. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 15(1):206\u2013211. https:\/\/doi.org\/10.1016\/0735-1097(90)90203-2","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"2833_CR36","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"issue":"15","key":"2833_CR37","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/eurheartj\/ehae649","volume":"46","author":"H Schunkert","year":"2025","unstructured":"Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E et al (2025) Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: a clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur Heart J 46(15):1372\u20131383. https:\/\/doi.org\/10.1093\/eurheartj\/ehae649","journal-title":"Eur Heart J"},{"issue":"20","key":"2833_CR38","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/eurheartj\/ehae048","volume":"45","author":"L Li","year":"2024","unstructured":"Li L, Pang S, Starnecker F, Mueller-Myhsok B, Schunkert H (2024) Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease. Eur Heart J 45(20):1843\u20131852. https:\/\/doi.org\/10.1093\/eurheartj\/ehae048","journal-title":"Eur Heart J"},{"key":"2833_CR39","doi-asserted-by":"publisher","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C et al (2025) 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J ehaf190.  https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","DOI":"10.1093\/eurheartj\/ehaf190"},{"key":"2833_CR40","doi-asserted-by":"publisher","unstructured":"(2023) SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44(28):2544\u20132556.  https:\/\/doi.org\/10.1093\/eurheartj\/ehad260","DOI":"10.1093\/eurheartj\/ehad260"},{"issue":"9","key":"2833_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016461","volume":"7","author":"LE Akioyamen","year":"2017","unstructured":"Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A et al (2017) Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 7(9):e016461. https:\/\/doi.org\/10.1136\/bmjopen-2017-016461","journal-title":"BMJ Open"},{"issue":"7","key":"2833_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ehjqcco\/qcad075","volume":"10","author":"S Molnar","year":"2024","unstructured":"Molnar S, Scharnagl H, Delgado GE, Kr\u00e4mer BK, Laufs U, M\u00e4rz W et al (2024) Clinical and genetic diagnosis of familial hypercholesterolaemia in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J Qual Care Clin Outcomes 10(7):632\u2013640. https:\/\/doi.org\/10.1093\/ehjqcco\/qcad075","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"3","key":"2833_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/eurjpc\/zwae331","volume":"32","author":"M Ferch","year":"2025","unstructured":"Ferch M, Galli L, Fellinger P, Baumgartner-Parzer S, Sunder-Plassmann R, Krychtiuk K et al (2025) Performance of LDL-C only compared to the Dutch Lipid Clinic Network Score for screening of familial hypercholesterolaemia: the Austrian experience and literature review. Eur J Prev Cardiol 32(3):249\u2013258. https:\/\/doi.org\/10.1093\/eurjpc\/zwae331","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"2833_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/eurpub\/ckac007","volume":"32","author":"V Sanin","year":"2022","unstructured":"Sanin V, Schmieder R, Ates S, Schlieben LD, Wiehler J, Sun R et al (2022) Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health 32(3):422\u2013428. https:\/\/doi.org\/10.1093\/eurpub\/ckac007","journal-title":"Eur J Public Health"},{"issue":"14","key":"2833_CR45","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","volume":"31","author":"SHJ Hageman","year":"2024","unstructured":"Hageman SHJ, Kaptoge S, de Vries TI, Lu W, Kist JM, van Os HJA et al (2024) Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Eur J Prev Cardiol 31(14):1690\u20131699. https:\/\/doi.org\/10.1093\/eurjpc\/zwae174","journal-title":"Eur J Prev Cardiol"},{"issue":"9602","key":"2833_CR46","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/s0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602):1829\u20131839. https:\/\/doi.org\/10.1016\/s0140-6736(07)61778-4","journal-title":"Lancet"},{"issue":"10106","key":"2833_CR47","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/s0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R et al (2017) Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390(10106):1962\u20131971. https:\/\/doi.org\/10.1016\/s0140-6736(17)32290-0","journal-title":"Lancet"},{"issue":"22","key":"2833_CR48","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/eurheartj\/ehaa1080","volume":"42","author":"AD Karagiannis","year":"2021","unstructured":"Karagiannis AD, Mehta A, Dhindsa DS, Virani SS, Orringer CE, Blumenthal RS et al (2021) How low is safe? The frontier of very low (<30 mg\/dL) LDL cholesterol. Eur Heart J 42(22):2154\u20132169. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1080","journal-title":"Eur Heart J"},{"key":"2833_CR49","doi-asserted-by":"publisher","unstructured":"O\u2019Keefe JH Jr., Cordain L, Harris WH, Moe RM, Vogel R (2004) Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal. J Am Coll Cardiol 43(11):2142\u20132146. https:\/\/doi.org\/10.1016\/j.jacc.2004.03.046","DOI":"10.1016\/j.jacc.2004.03.046"},{"issue":"3","key":"2833_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/fjc.0000000000000963","volume":"77","author":"I Farmakis","year":"2021","unstructured":"Farmakis I, Doundoulakis I, Pagiantza A, Zafeiropoulos S, Antza C, Karvounis H et al (2021) Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis. J Cardiovasc Pharmacol 77(3):397\u2013407. https:\/\/doi.org\/10.1097\/fjc.0000000000000963","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"2833_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/coh.0000000000000227","volume":"11","author":"CT Longenecker","year":"2016","unstructured":"Longenecker CT, Sullivan C, Baker JV (2016) Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS 11(2):216\u2013225. https:\/\/doi.org\/10.1097\/coh.0000000000000227","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"2833_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1381612824666180110102341","volume":"24","author":"PR Hansen","year":"2018","unstructured":"Hansen PR (2018) Chronic inflammatory diseases and atherosclerotic cardiovascular disease: innocent bystanders or partners in crime? Curr Pharm Des 24(3):281\u2013290. https:\/\/doi.org\/10.2174\/1381612824666180110102341","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2833_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/heartjnl-2017-311279","volume":"104","author":"JM Baena-D\u00edez","year":"2018","unstructured":"Baena-D\u00edez JM, Garcia-Gil M, Comas-Cuf\u00ed M, Ramos R, Prieto-Alhambra D, Salvador-Gonz\u00e1lez B et al (2018) Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart 104(2):119\u2013126. https:\/\/doi.org\/10.1136\/heartjnl-2017-311279","journal-title":"Heart"},{"issue":"8","key":"2833_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA et al (2023) Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 389(8):687\u2013699","journal-title":"N Engl J Med"},{"issue":"10","key":"2833_CR55","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/heartjnl-2015-307838","volume":"102","author":"R Agca","year":"2016","unstructured":"Agca R, Heslinga SC, van Halm VP, Nurmohamed MT (2016) Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 102(10):790\u2013795. https:\/\/doi.org\/10.1136\/heartjnl-2015-307838","journal-title":"Heart"},{"issue":"23","key":"2833_CR56","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/heartjnl-2017-311214","volume":"103","author":"A Dregan","year":"2017","unstructured":"Dregan A, Chowienczyk P, Molokhia M (2017) Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart 103(23):1867\u20131873. https:\/\/doi.org\/10.1136\/heartjnl-2017-311214","journal-title":"Heart"},{"issue":"1","key":"2833_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA (2020) Clinical review on triglycerides. Eur Heart J 41(1):99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785","journal-title":"Eur Heart J"},{"issue":"9943","key":"2833_CR58","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626\u2013635. https:\/\/doi.org\/10.1016\/s0140-6736(14)61177-6","journal-title":"Lancet"},{"issue":"12","key":"2833_CR59","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","volume":"374","author":"NO Stitziel","year":"2016","unstructured":"Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, K\u00f6nig IR et al (2016) Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374(12):1134\u20131144. https:\/\/doi.org\/10.1056\/NEJMoa1507652","journal-title":"N Engl J Med"},{"issue":"1","key":"2833_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"6","key":"2833_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR et al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 381(6):531\u2013542","journal-title":"N Engl J Med"},{"issue":"25","key":"2833_CR62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas M-I, Corella D, Ar\u00f3s F et al (2018) Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 378(25):e34. https:\/\/doi.org\/10.1056\/NEJMoa1800389","journal-title":"N Engl J Med"},{"issue":"5","key":"2833_CR63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3945\/ajcn.2010.29673","volume":"92","author":"F Sofi","year":"2010","unstructured":"Sofi F, Abbate R, Gensini GF, Casini A (2010) Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 92(5):1189\u20131196. https:\/\/doi.org\/10.3945\/ajcn.2010.29673","journal-title":"Am J Clin Nutr"},{"issue":"27","key":"2833_CR64","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1055\/s-0034-1370134","volume":"139","author":"N Weing\u00e4rtner","year":"2014","unstructured":"Weing\u00e4rtner N, Els\u00e4sser A, Weing\u00e4rtner O (2014) [Dietary supplements and cardiovascular diseases]. Dtsch Med Wochenschr 139(27):1423\u20131426. https:\/\/doi.org\/10.1055\/s-0034-1370134","journal-title":"Dtsch Med Wochenschr"},{"issue":"11","key":"2833_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11883-021-00964-x","volume":"23","author":"U Makhmudova","year":"2021","unstructured":"Makhmudova U, Schulze PC, L\u00fctjohann D, Weing\u00e4rtner O (2021) Phytosterols and cardiovascular disease. Curr Atheroscler Rep 23(11):68. https:\/\/doi.org\/10.1007\/s11883-021-00964-x","journal-title":"Curr Atheroscler Rep"},{"issue":"24","key":"2833_CR66","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):e285\u2013e350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003","journal-title":"J Am Coll Cardiol"},{"issue":"10059","key":"2833_CR67","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532\u20132561. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"issue":"1","key":"2833_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01265-9","volume":"27","author":"RD Paparodis","year":"2024","unstructured":"Paparodis RD, Bantouna D, Livadas S, Angelopoulos N (2024) Statin therapy in primary and secondary cardiovascular disease prevention. Curr Atheroscler Rep 27(1):21. https:\/\/doi.org\/10.1007\/s11883-024-01265-9","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"2833_CR69","doi-asserted-by":"publisher","first-page":"Cd004816","DOI":"10.1002\/14651858.CD004816.pub5","volume":"2013","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013(1):Cd004816. https:\/\/doi.org\/10.1002\/14651858.CD004816.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"34","key":"2833_CR70","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A et al (2022) Prevalence of statin intolerance: a meta-analysis. Eur Heart J 43(34):3213\u20133223. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015","journal-title":"Eur Heart J"},{"issue":"4","key":"2833_CR71","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA et al (2022) NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 16(4):361\u2013375. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.068","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2833_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","volume":"10","author":"JA Tobert","year":"2016","unstructured":"Tobert JA, Newman CB (2016) The nocebo effect in the context of statin intolerance. J Clin Lipidol 10(4):739\u2013747. https:\/\/doi.org\/10.1016\/j.jacl.2016.05.002","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2833_CR73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2047487312451251","volume":"20","author":"S Stender","year":"2013","unstructured":"Stender S, Budinski D, Gosho M, Hounslow N (2013) Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 20(1):40\u201353. https:\/\/doi.org\/10.1177\/2047487312451251","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"2833_CR74","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388(15):1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024","journal-title":"N Engl J Med"},{"key":"2833_CR75","doi-asserted-by":"publisher","unstructured":"Bohula EA, Marston NA, Bhatia AK, Ferrari GMD, Leiter LA, Nicolau JC et al Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2514428","DOI":"10.1056\/NEJMoa2514428"},{"issue":"40","key":"2833_CR76","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","volume":"41","author":"A Allahyari","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstr\u00f6m E, Leosdottir M, Lundman P, Ueda P (2020) Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J 41(40):3900\u20133909. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa034","journal-title":"Eur Heart J"},{"issue":"39","key":"2833_CR77","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","volume":"45","author":"J Schubert","year":"2024","unstructured":"Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A et al (2024) Intensive early and sustained lowering of non\u2013high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. Eur Heart J 45(39):4204\u20134215. https:\/\/doi.org\/10.1093\/eurheartj\/ehae576","journal-title":"Eur Heart J"},{"issue":"15","key":"2833_CR78","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","volume":"85","author":"M Leosdottir","year":"2025","unstructured":"Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundstr\u00f6m J et al (2025) Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol 85(15):1550\u20131564. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.007","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2833_CR79","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, R\u00f6mer R et al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d). Clin Res Cardiol 112(9):1212\u20131219. https:\/\/doi.org\/10.1007\/s00392-022-02147-3","journal-title":"Clin Res Cardiol"},{"issue":"29","key":"2833_CR80","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","volume":"38","author":"N Hagiwara","year":"2017","unstructured":"Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K et al (2017) Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 38(29):2264\u20132276. https:\/\/doi.org\/10.1093\/eurheartj\/ehx162","journal-title":"Eur Heart J"},{"issue":"9860","key":"2833_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381(9860):40\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(12)61731-0","journal-title":"Lancet"},{"key":"2833_CR82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","volume":"274","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK et al (2024) Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J 274:32\u201345. https:\/\/doi.org\/10.1016\/j.ahj.2024.05.002","journal-title":"Am Heart J"},{"key":"2833_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.010","volume":"368","author":"S Stankov","year":"2023","unstructured":"Stankov S, Cuchel M (2023) Gene editing for dyslipidemias: new tools to \u201ccut\u201d lipids. Atherosclerosis 368:14\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.01.010","journal-title":"Atherosclerosis"},{"issue":"7859","key":"2833_CR84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW et al (2021) In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593(7859):429\u2013434. https:\/\/doi.org\/10.1038\/s41586-021-03534-y","journal-title":"Nature"},{"issue":"7","key":"2833_CR85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF et al (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 3(7):619\u2013627. https:\/\/doi.org\/10.1001\/jamacardio.2018.1470","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2833_CR86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","volume":"4","author":"C Lamina","year":"2019","unstructured":"Lamina C, Kronenberg F (2019) Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis. JAMA Cardiol 4(6):575\u2013579. https:\/\/doi.org\/10.1001\/jamacardio.2019.1041","journal-title":"JAMA Cardiol"},{"issue":"25","key":"2833_CR87","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 59(25):2344\u20132353. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.007","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2833_CR88","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL (2020) Statin therapy increases lipoprotein(a) levels. Eur Heart J 41(24):2275\u20132284. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310","journal-title":"Eur Heart J"},{"key":"2833_CR89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415818","author":"SE Nissen","year":"2025","unstructured":"Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ et al (2025) Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415818","journal-title":"N Engl J Med"},{"issue":"20","key":"2833_CR90","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ et al (2022) Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 387(20):1855\u20131864. https:\/\/doi.org\/10.1056\/NEJMoa2211023","journal-title":"N Engl J Med"},{"issue":"3","key":"2833_CR91","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382(3):244\u2013255. https:\/\/doi.org\/10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"issue":"23","key":"2833_CR92","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG et al (2024) Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA 332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957","journal-title":"JAMA"},{"issue":"3","key":"2833_CR93","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF et al (2025) Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 333(3):222\u2013231. https:\/\/doi.org\/10.1001\/jama.2024.24017","journal-title":"JAMA"},{"issue":"12","key":"2833_CR94","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/s0002-9149(98)00692-4","volume":"82","author":"H Mabuchi","year":"1998","unstructured":"Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K et al (1998) Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group Am J Cardiol 82(12):1489\u20131495. https:\/\/doi.org\/10.1016\/s0002-9149(98)00692-4","journal-title":"Am J Cardiol"},{"issue":"24","key":"2833_CR95","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/circulationaha.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567\u20132576. https:\/\/doi.org\/10.1161\/circulationaha.113.002432","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02833-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02833-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02833-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:37:22Z","timestamp":1768995442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02833-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2833"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02833-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PS consulted for Novartis, and HS consulted for AstraZeneca, BayerVital, Daiichi Sankyo, MSD\/Merck, Novartis, Sanofi, Servier, Amgen and Takeda Pharma. JLK received honoraria and\/or travel grants from Daiichi Sankyo, Novartis, Synlab, Boehringer Ingelheim, and Lilly. UL received honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi. UL received research support or payment from Abbott, Amgen, Novartis, Merck Sharp&Dohme, Sanofi, Menarini from Amgen, Daiichi Sankyo, Novartis, and Sanofi. TFL does not accept any honoraria from industry, but received educational and research grants from Abbott, Amgen, Alnylam, AstraZeneca, BAYER, Boehringer Ingelheim, Cytokinetics, Daichi-Sankyo, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, and Vifor.The manuscript reflects some of the ideas discussed at the 38th Symposium of the Walter-Siegenthaler-Gesellschaft 2024 in Cologne entitled \u201cThe pharmacologic revolution \u2013 nuclear acids as therapeutic agents in internal medicine\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}